Loading resource…

AMUNDSEN Investigators of the ACTION Study Group
The AMUNDSEN Randomized Clinical Trial evaluates the efficacy of evolocumab in lowering LDL cholesterol before percutaneous coronary intervention in patients with acute myocardial infarction. The trial highlights the importance of achieving optimal LDL cholesterol levels to improve clinical outcomes in this high-risk population. Results indicate that a significant proportion of patients achieved LDL cholesterol levels below recommended thresholds, suggesting the potential for enhanced lipid management strategies in acute care settings.
No account needed